Recent tau-targeted clinical strategies for the treatment of Alzheimer's disease

Interestingly, LMTX has shown initial promise as a monotherapy for mild-to-moderate AD patients who have not taken other AD drugs. [...]another Phase II/III clinical trial of LMTX was launched to further investigate safety and efficacy as a monotherapy to early AD patients (NCT03446001). Pharmacological inhibition of p300 with salsalate in PS19 mice reduced the level of acetylated tau at K174 subsequently ameliorating hippocampal atrophy and memory deficits (10), which suggests perturbing tau acetylation could be an effective therapeutic strategy for AD and tauopathies. [...]pilot futility clinical trial of salsalate (NCT02422485) was launched to confirm the preliminary efficacy, safety and tolerability with progressive supranuclear palsy (PSP) patients. [...]Phase II clinical trials have been initiated with patients with PSP (NCT03068468, NCT03391765) and mild AD (NCT03352557, NCT03712787) with these two antibodies, respectively. [...]thorough analysis of clinical trials with tau-targeted drug candidates as well as other AD trials will eventually help to develop disease-modifying therapeutics for AD.